• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

    1/10/23 12:37:35 PM ET
    $SYNH
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SYNH alert in real time by email
    SC 13G/A 1 tv0012-syneoshealthinc.htm SCHEDULE 13G/A syneoshealthinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 8)*

    Name of issuer:  Syneos Health Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  87166B102

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  87166B102

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    96,524

    7.  SOLE DISPOSITIVE POWER

    10,145,901

    8.  SHARED DISPOSITIVE POWER

    200,386

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,346,287

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.05%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Syneos Health Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1030 Sync Street
    Morrisville, NC 27560-5468

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    87166B102

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  January 10, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $SYNH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYNH

    DatePrice TargetRatingAnalyst
    2/13/2023$30.00 → $28.00Neutral → Underweight
    JP Morgan
    1/17/2023$30.00 → $25.00Overweight → Underweight
    Barclays
    1/13/2023$25.00Overweight → Underweight
    Barclays
    12/14/2022$66.00 → $38.00Buy → Neutral
    Mizuho
    11/7/2022$55.00 → $27.00Outperform → In-line
    Evercore ISI
    10/18/2022$85.00 → $53.00Overweight → Neutral
    JP Morgan
    9/14/2022Buy → Neutral
    Guggenheim
    9/7/2022$68.00Neutral
    UBS
    More analyst ratings

    $SYNH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.

      JERSEY CITY, N.J., April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in the United States (U.S.). In 2016, MTPA was created as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of developing and advancing the company's pipeline in the U.S. while focusing on improving research in the areas of amyotrophic lateral sclerosis (ALS), erythropoietic protoporphyria (EPP), Parkinson's disease, spinal cord injury and systemic sclerosis. "For almost a decade, MT

      4/29/24 9:00:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting

      Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight results from Phase 3 BouNDless trial in PD and real-world findings from preliminary analysis of RADICAVA® (edaravone) treatment in ALSJERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024. The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).

      4/12/24 9:00:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)

      Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care  JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS). The FDA's Orphan Drug program is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the U.S. Previously, the FDA granted RADIC

      4/8/24 9:00:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Syneos Health downgraded by JP Morgan with a new price target

      JP Morgan downgraded Syneos Health from Neutral to Underweight and set a new price target of $28.00 from $30.00 previously

      2/13/23 7:39:42 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health downgraded by Barclays with a new price target

      Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00 from $30.00 previously

      1/17/23 9:22:20 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health downgraded by Barclays with a new price target

      Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00

      1/13/23 9:04:42 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    SEC Filings

    See more
    • SEC Form 15-12G filed by Syneos Health Inc.

      15-12G - Syneos Health, Inc. (0001610950) (Filer)

      10/10/23 6:08:58 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 8-K filed by Syneos Health Inc.

      8-K - Syneos Health, Inc. (0001610950) (Filer)

      10/3/23 8:12:59 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by Syneos Health Inc.

      S-8 POS - Syneos Health, Inc. (0001610950) (Filer)

      9/28/23 12:32:55 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

      SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)

      6/9/23 10:14:20 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

      SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)

      2/6/23 2:58:20 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

      SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)

      1/23/23 3:52:32 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE:CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE:HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29. Elliot Investment Management is acquiring Syneos Health in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector September 29, 2023 S&P MidCap 400 Addition Civitas Resources

      9/26/23 5:41:00 PM ET
      $CIVI
      $HAYW
      $SPGI
      $SYNH
      Oil & Gas Production
      Energy
      Industrial Machinery/Components
      Industrials
    • Syneos Health Names Terttu Haring President, Clinical Sites & Patients

      MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organization to drive exceptional delivery, quality and data integrity for customers, while ensuring a positive experience for sponsors, sites and patients. Her investigator background, and technology and data experience, will empower the Clinical Sites & Patients team to execute data-driven solutions that produce strong results for customers. Under Dr. Haring'

      9/26/23 7:30:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Financials

    Live finance-specific insights

    See more
    • Syneos Health Stockholders Approve Agreement with Private Investment Consortium

      MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company's stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing o

      8/2/23 8:47:45 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion

      Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management ("Elliott"), Patient Square Capital ("Patient Square"), and Veritas Capital ("Veritas") for $43.00 per share in cash in a transaction valued at approximately $7.1 billion, including outstanding debt. The purchase price represents a

      5/10/23 6:47:41 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023

      MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET. To listen only and view the presentation slides via the live webcast, join from the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register in advance at this link. Upon registration, all participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uni

      4/13/23 4:31:00 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)

      4 - Syneos Health, Inc. (0001610950) (Issuer)

      9/28/23 5:08:43 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)

      4 - Syneos Health, Inc. (0001610950) (Issuer)

      9/28/23 5:08:14 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Monaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)

      4 - Syneos Health, Inc. (0001610950) (Issuer)

      9/28/23 5:07:50 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care